-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Selection of Bispecific Antibody Therapies or CAR T-Cell Therapy in Relapsed Lymphomas

Program: Education Program
Session: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, B Cell lymphoma, Diseases, aggressive lymphoma, Therapies, therapy sequence, Lymphoid Malignancies
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Manali K. Kamdar, MD, MBBS

University of Colorado,, Denver, CO

Disclosures: Kamdar: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, syncopation, caribou biosciences: Consultancy; Genentech, Celgene: Other: DMC; Novartis: Research Funding; SeaGen: Speakers Bureau.

See more of: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
See more of: Education Program
<< Previous Presentation | Next Presentation